Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Today's Bonus News 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Published 12/12/2025. 
Key Points - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is a requirement. Most of these companies are still in the clinical stage, meaning they have no commercially available drugs or therapeutics. It also means these companies have negative earnings (i.e., are not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. Elon Musk's Starlink project is generating major speculation ahead of a potential IPO that some analysts believe could reach a historic $100 billion valuation. According to James Altucher, there may be a smart "backdoor" way for everyday investors to position ahead of that event without needing traditional IPO access — and he says it can be done for under $100. He's also sharing a free ticker tied to this trend for anyone who wants to take a closer look. Click here to learn more Even if a product advances through trials, profitability may still be years away. Only after reaching that milestone do companies typically attract the analyst coverage that brings institutional investment. However, getting in on one of these medical stocks before it breaks can yield outsized returns. In a short period, investors could see 3x, 5x, or even 10x returns. Others may never pan out. That's why many investors in penny stocks spread a lump sum across multiple biotech names. If it is a numbers game, diversification can be an effective strategy. With that in mind, let's examine two small-cap biotech stocks that carry significant risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company that specializes in epigenetics-based tests for early cancer detection. Unlike some penny stocks in this space, Mainz Biomed has a commercially available product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany’s leading pioneers in digital health. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is meaningful. The company is also developing a non-invasive blood-based screening test for early detection of pancreatic cancer and reported positive topline results in October. That program, however, is years away from potential commercial approval. Risks remain substantial. ColoAlert is not yet available in the United States, and despite early European sales and plans to expand into South America, revenue is currently minimal. The company included “Going Concern” language in its Sept. 26 SEC filing, and it has since filed for a $150 million mixed shelf offering. That financing has helped keep MYNZ above $1 for now, avoiding a delisting notice. Mainz Biomed is in a race to generate meaningful revenue. If it succeeds, even a modest investment could produce a sizable return; if not, the stock could face significant downside. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech that proposes a potentially disruptive approach to antiviral treatment—but it also carries the financial risks speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces and lure viruses into binding with them, effectively neutralizing the pathogens before they can infect real cells. It’s an innovative concept that, if validated in human trials, could represent a new class of treatments for infectious diseases. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has produced encouraging preclinical data suggesting strong antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and is reliant on fresh capital to advance its programs. Recent filings show limited cash on hand, so investors should expect the possibility of future dilution. Still, if even one candidate successfully progresses into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
